# A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients

## TL;DR

Combining CT-guided radiofrequency ablation with targeted therapy improves lung cancer treatment outcomes and survival rates compared to targeted therapy alone.

## Contribution

Demonstrates that combining CT-guided radiofrequency ablation with targeted therapy improves clinical outcomes in lung cancer patients.

## Key findings

- The Observation Group had higher Overall Response Rate and Disease Control Rate compared to the Control Group.
- The 24-month survival rate was significantly higher in the Observation Group.
- The Observation Group showed better biomarker profiles after treatment.

## Abstract

The study aimed to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG; n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG; n=40, treated solely with targeted therapy).

The Overall Response Rate (ORR) and Disease Control Rate (DCR) in the OG group (70.00%, 95.00%) were significantly higher than those in the CG group (57.50%, 87.50%). After 6 weeks of treatment, the OG group had significantly lower levels of SCC, CEA, and CA125, higher CD4+ levels, and lower CD8+ levels, compared to the CG group. The 24-month follow-up survival rate of the OG group (47.50%) was significantly higher than that of the CG group (27.50%).

CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.